New state-of-the-art micro-ultrasound/MRI fusion application profiled as part of the latest urological targeted imaging technologies

TORONTO, Oct. 17, 2017 /PRNewswire/ - Exact Imaging (www.exactimaging.com), the world's leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, today shared the company's comprehensive Fall schedule to demonstrate its new FusionVu™ application. Exact Imaging, recognized as a key technology solution in the targeted prostate biopsy market, will be profiling and demonstration its FusionVu application at the following 3 leading urological medical conferences' HOT ("Hands-On Training") workshops:

"We are excited to participate for the first time in three leading global workshops on ultrasound/MR Fusion technologies and profile our ExactVu platform and FusionVu application," says Randy AuCoin, Exact Imaging's President and CEO. "Urologists worldwide are desperate for better biopsy targeting solutions and our ExactVu platform provides the highest resolution real-time targeting approach. Should there be a requirement to include MR imaging, FusionVu provides the fastest, simplest fusion solution. FusionVu incorporate MR images onto the ExactVu platform to perform cognitive targeting (called Cognitive Assist™) or fully aligns MR images to enable micro-ultrasound/MRI fusion-based targeting. Participating in these world-class workshops is an excellent forum to highlight our technology".

In addition to these workshops, the ExactVu/FusionVu product offering will also be demonstrated at several leading global urological conferences. A complete list of these conferences is available at www.exactimaging.com/conferences-and-events. 

About Exact Imaging:

Exact Imaging (www.exactimaging.com)is the world's leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging's ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas, aided by the PRI-MUS™ (prostate risk identification using micro-ultrasound) evidence-based micro-ultrasound protocol. For the minority of cases where MRI might assist (i.e., prior negative biopsies), FusionVu™ is the forthcoming micro-US/MRI fusion application operating on the ExactVu micro-ultrasound platform. The ExactVu micro-ultrasound system has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).

SOURCE Exact Imaging